Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases

Table 1 Baseline characteristics of the Dutch hospital-based ORIGO cohort of breast cancer patients (n = 1267)

Variable	Value
Age at diagnosis (years) (n = 1,254)	54 ± 11.2 (21–88)
Follow-up time (months) (n = 476)	64 ± 31 (3–126)
Body mass index (kg/m²) (n = 1,203)	25 ± 4 (16–45)
Sex (n = 1,267)
Female	1262 (99.6%)
Male	5 (0.4%)
Bilaterality of breast cancer^a (n = 1,265)
Bilateral	79 (6.2%)
Unilateral	1186 (93.8%)
Tumour characteristics
Bloom–Richardson grade (n = 964)
Grade I	175 (18.2%)
Grade II	399 (41.4%)
Grade III	390 (40.5%)
Clinical staging of cancer (UICC)^b (n = 1,230)
Stage 0 (in situ)	144 (11.7%)
Stage 1	479 (38.9%)
Stage 2	526 (42.8%)
Stage 3	81 (6.6%)
Receptor status
Oestrogen receptor (n = 831)
Positive	597 (71.8%)
Negative	234 (28.2%)
Progesterone receptor (n = 683)
Positive	399 (58.4%)
Negative	284 (41.6%)
Human epidermal growth factor receptor 2 (HER2/neu) (n = 76)
Positive	14 (18.4%)
Negative	62 (81.6%)
Risk factors
Family history^c (n = 1,253)
Negative	753 (60.1%)
Positive	500 (39.9%)
Pregnancy (n = 1,179)
Ever	968 (82.1%)
Never	211 (17.9%)
Breastfeeding (n = 1,215)
Ever	693 (57%)
Never	522 (43%)
Breastfeeding duration (months)	5.21 ± 9.8 (0–121)

Data presented as the mean ± standard deviation (range) or number (% of total number). ^aWithin 6 months of first diagnosis. ^bInternational Union Against Cancer (UICC) stages, based on T classification and N classification, known in 1,230 patients. ^cFamily history is considered positive when at least one first-degree or second-degree relative also had breast cancer, irrespective of age at onset.

ISSN: 1465-542X